We also observed that p16 deletion could ameliorate the microbiota dysbiosis and decrease the inflammation level in Bmi-1–deficient mice, which provides potential targets for the treatment of age-associated intestinal diseases and intestinal microbiota dysfunction. This evidence concerns the gene CDKN2A and intestinal disorder.